ODYSSEY ESCAPE: is PCSK9 inhibition the Trojan Horse for the use of lipoprotein apheresis in familial hypercholesterolaemia?

Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular DiseaseHighlights

(2016) Eberhard Roeseler et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL, without lowering HDL cholesterol

(2016) Knut Tore Lappegård et al.   ATHEROSCLEROSIS

Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial

(2016) Patrick M. Moriarty et al.   EUROPEAN HEART JOURNAL

Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: Rationale and design of the ODYSSEY ESCAPE trial

(2016) Patrick M. Moriarty et al.   Journal of Clinical Lipidology

Quality of life in patients treated with lipoprotein apheresis

(2016) Adrian Rosada et al.   Journal of Clinical Lipidology

Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism

(2016) Katrina L. Ellis et al.   Nature Reviews Endocrinology

Systematic Review of Low‐Density Lipoprotein Cholesterol Apheresis for the Treatment of Familial Hypercholesterolemia

(2016) Anthony Wang et al.   Journal of the American Heart Association

Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel

(2016) Raul D Santos et al.   Lancet Diabetes & Endocrinology

ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia

(2015) John J.P. Kastelein et al.   EUROPEAN HEART JOURNAL

Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?

(2015) Robert P. Giugliano et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

(2015) Frederick J Raal et al.   LANCET

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

(2015) Frederick J Raal et al.   LANCET

PCSK9

(2014) Nabil G. Seidah et al.   CIRCULATION RESEARCH

Lipoprotein Apheresis in the Management of Familial Hypercholesterolaemia: Historical Perspective and Recent Advances

(2014) Claudia Stefanutti et al.   Current Atherosclerosis Reports

Lipoprotein(a) Levels in Familial Hypercholesterolemia

(2014) Rodrigo Alonso et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Loss of Plasma Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) After Lipoprotein Apheresis

(2013) Hagai Tavori et al.   CIRCULATION RESEARCH